Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The purpose of this study is to assess the safety and tolerability of multiple dose administration of gefapixant (MK‐7264) in participants with moderate to severe obstructive sleep apnea (OSA). The primary hypothesis is that multiple dose administration of gefapixant (MK‐7264) in participants with moderate to severe OSA reduces the Apnea Hypopnea Index (AHI) relative to placebo.
Epistemonikos ID: 63cb61689d25d8cea244ac12fca126e570b70c7c
First added on: May 22, 2024